This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued
April is a full month at OCRA, with several new programs joining our ongoing lineup of workshops, educational sessions, and community events. Whether you’re looking for practical guidance, clinical information, or simply a chance to connect and create, there’s something here for you. New and Expanded Programs Advanced Care Planning Workshop Series April 6, 13, … Continued
Written by Julia Thayer, Associate Director, Advocacy This month, more than 120 OCRA Advocate Leaders traveled to Washington, DC for Advocacy Day—braving snowstorms, severe weather, and even a partial government shutdown to make their voices heard on Capitol Hill. We kicked things off with a full day of training, where the group built skills, shared stories, and … Continued
On March 17, 122 Advocate Leaders from nearly 40 states and Washington, DC, converged on Capitol Hill for OCRA’s Spring Advocacy Day. Together, they held 158 meetings with Congressional offices, carrying a clear message: Congress must sustain and build on its commitment to ovarian and gynecologic cancer research. The energy and reach of this year’s … Continued
On March 17, Ovarian Cancer Research Alliance (OCRA) Advocate Leaders from across the country will be on Capitol Hill for OCRA’s Spring Advocacy Day—and we need your voice, too. If you can’t join us in person, please take action to reinforce our efforts on the Hill and help us make a big impact. Advocacy Day Priorities This … Continued
Cool Hand Frank, a digital publication that spotlights nonprofits making a difference, has named Ovarian Cancer Research Alliance (OCRA) its featured cause for March 2026, spotlighting OCRA’s work in advancing ovarian and gynecologic cancer research and supporting patients and their loved ones. The publication cited a deeply personal connection to the cause, with the author … Continued
OCRA is excited to see the work fueled by our new AI Accelerator Grant resonating with a broad array of audiences. Since the Global Ovarian Cancer Research Consortium announced the inaugural AI Accelerator Grant on February 19, coverage has appeared across health, science, and business media outlets. The $1 million global research award—with an additional … Continued
The Global Ovarian Cancer Research Consortium and its inaugural AI Accelerator Grant have been making waves across health, science, and business media, reflecting widespread interest in what this work could mean for patients. The $1 million global research grant, plus an additional $1 million in compute support from Microsoft’s AI for Good Lab, will fund … Continued
Written by Chad Ramsey, Vice President, Policy February brought meaningful progress in Washington. From major legislative wins to the start of a new appropriations cycle, advocates are already helping shape the policy landscape for ovarian and gynecologic cancer patients in 2026 and beyond. State-Level Momentum: Biomarker Progress Continues Momentum is building across the country to … Continued
Recognizing Advances in Ovarian Cancer Research and Immunotherapy Ovarian Cancer Research Alliance (OCRA) announced today the winners of two prizes recognizing exceptional accomplishments in ovarian cancer research. David Huntsman, MD, FRCPC, FCCMG, was awarded the 2025 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research for his findings that have profoundly impacted the treatment of … Continued
Get email updates about research news, action alerts, and ways to join the fight.
